Sideroblastic anemia after prolonged linezolid therapy

DOI Web Site 5 References
  • KAKIMOTO Tsunayuki
    Department of Hematology, Yokohama Municipal Citizen's Hospital
  • NAKAZATO Tomonori
    Department of Hematology, Yokohama Municipal Citizen's Hospital
  • MIURA Reiko
    Center for Rheumatology, Collagen disease and Gout, Toho University Ohashi Medical Center
  • KURAI Hanako
    Department of Infectious Disease, Yokohama Municipal Citizen's Hospital
  • YAMASHITA Daisuke
    Department of Otorhinolaryngology, Head & Neck Surgery, Keio University School of Medicine
  • SAGARA Yuko
    Department of Infectious Disease, Yokohama Municipal Citizen's Hospital
  • ISHIDA Akaru
    Department of Internal Medicine, Kyosai Tachikawa Hospital

Bibliographic Information

Other Title
  • リネゾリド長期投与による鉄芽球性貧血
  • リネゾリド チョウキ トウヨ ニ ヨル テツ ガキュウセイ ヒンケツ

Search this article

Abstract

Linezolid is an effective and well-tolerated antibiotic for the treatment of infections caused by Gram-positive pathogens. Some reports have shown that linezolid treatment for more than 2 weeks has been associated with reversible bone marrow suppression, especially thrombocytopenia and anemia. We encountered a case of sideroblastic anemia following prolonged linezolid therapy in a laryngeal cancer patient. He received linezolid therapy for multiple abscesses due to MRSA. Before treatment, the Hb level was 12.5 g/dl and then slowly decreased to 5.9 g/dl for 2 months during treatment. Ringed sideroblasts were detected in the bone marrow. Linezolid was discontinued and the Hb level was slowly increased. This case was considered to reflect a rare complication of linezolid therapy.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 49 (11), 1566-1568, 2008

    The Japanese Society of Hematology

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top